Lexology November 12, 2024
Jones Day

The U.S. Food and Drug Administration’s (“FDA”) new advisory committee on digital health is set to examine its approach for evaluating and regulating the safety and effectiveness of medical devices utilizing generative artificial intelligence (“GenAI”) at its initial meeting, receiving stakeholder insight regarding premarket performance evaluation, risk management, and postmarket performance monitoring.

FDA’snew Digital Health Advisory Committee (“DHAC”) will hold its first meeting on November 20-21, 2024, in Gaithersburg, Maryland, to discuss total product lifecycle considerations for GenAI-enabled medical devices, including how the use of artificial intelligence may impact the safety and effectiveness of medical devices and approaches to regulation. The newly constituted DHAC includes nine voting members; FDA may, but is not required to, supplement the DHAC with temporary,...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: AI (Artificial Intelligence), Digital Health, FDA, Govt Agencies, Medical Devices, Technology
This Bill Could Make It Legal for AI to Prescribe Medicine
STAT+: Trump’s FDA navigates layoffs, exits, and a new hire
Substantial portion of cancer patients in early trials access drugs that are later approved, study finds
The GLP-1 shortage is over. What’s next for compounders?
With RFK Jr. in Charge, Supplement Makers See Chance To Cash In

Share This Article